Estimates Revisions ARS Pharmaceuticals, Inc.
Stocks
SPRY
US82835W1080
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.940 USD | -1.00% |
|
-20.38% | -49.01% |
| 07-18 | Ars Pharmaceuticals, Inc. Announces Management Changes, Effective July 15, 2026 | CI |
| 07-08 | ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- SPRY Stock
- Consensus ARS Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
